The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic- Dysfunction Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in three to four adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (two in three) and MASH with fibrosis (one in five) in adults with obesity and diabetes. This review summarizes the role of glucagon-like peptide (GLP) -1 receptor agonists in treating MASLD/MASH. Although not approved by the Food and Drug Administration for the treatment of MASLD, this class of medication is available to treat obesity and type 2 diabetes and has been shown to reverse steatohepatitis, reduce cardiovascular risk, and is safe to use across the spectrum of MASLD with or without fibrosis.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Layla A. Abushamat, Pir Ahmad Shah, Robert H. Eckel, Stephen A. Harrison, Diana Barb Tags: Narrative Reviews Source Type: research
More News: Cardiology | Cardiovascular | Cirrhosis | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Food and Drug Administration (FDA) | Gastroenterology | Heart | Insulin | Liver | Liver Disease | Obesity | Urology & Nephrology